Get notified when APUS files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Critical incident detected

Existential event · Existential event

Time-sensitive event — see the red-flag panel below for the source-quoted detail.

Red Flags Detected

  • Going Concern (worsened) — Language strengthened from 'existing cash insufficient' to explicit 'substantial doubt about ability to continue as going concern' despite IPO and PIPE financing.
  • Debt Default (new) — Company disclosed existing events of default on $11M convertible note within 5 months of issuance, requiring forbearance through June 30, 2026.
  • Material Weakness (worsened) — Controls assessment reversed from effective to ineffective; material weakness now explicitly attributed to inadequate segregation of duties with acknowledgment it will persist due to resource constraints.
NYSE: APUS Apimeds Pharmaceuticals US, Inc. 10-K

APUS merges with Bitcoin treasury firm, defaults on $11M debt, discloses control weakness

Filed May 4, 2026 · Period ending December 31, 2025 · Compared to 10-K Apr 15, 2025 · ~2 min read

Key Changes

  • high

    Company completed reverse merger with MindWave Innovations, shifting from pure biopharmaceutical to dual-subsidiary model with $146M in digital assets (Bitcoin, USDT, NILA tokens). MindWave shareholders now own 90.9% of combined entity.

    Business: Merger with MindWave verify on EDGAR →
  • high

    Company in default on $11M convertible note issued at merger closing; forbearance agreement runs through June 30, 2026 at lender's discretion. Going concern doubt explicitly stated despite IPO and PIPE financing.

    MD&A: Forbearance Agreement verify on EDGAR →
  • high

    Management reversed disclosure controls assessment from effective (2024) to ineffective (2025) due to material weakness in segregation of duties. Limited accounting staff means individuals handle authorization, recording, and review of same transactions.

    Controls: Material Weakness verify on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (FNGR 10-Q) is open in full — no account needed.

Partner

Trade APUS commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov View full financials on EDGAR ↗

Source-verified from EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify